Cytochrome P450 2D6
Layman’s Synopsis of 2D6 & lack of that pathway in some
leading to disasterNational Coalition of Organized Women
From Laboring Women to Labor Unions, We Move as One
www.ProgressiveConvergence.com
From the desk of the Director: 2011
An argument for genetic testing in mental illness as “Standard of Care”:
Toxic Sensitivity Behavior Performance (TSBP) or the more dangerous Iatrogenic
Sociopathic Syndrome (ISS) induced by a physician, by medical treatment or
diagnostic procedures puts the public at great risk. Homicides, school
shootings, random acts of violence, mental illness and suicides are on a
meteoric rise since the introduction of anti depressants, SSRIs and other modern
psyche drugs.
An “inadvertent” induction of TSBP or ISS by a psychiatrist can no longer serve
as a credible or legal excuse for iatrogenic harm to the patient and safety risk
to the public at large considering the wealth of research, science-based
evidence and clinical reports since the mapping of genes and the identification
of GENETIC POLYMORPHISMS OF CYTOCHROME P450 (CYP) 2D6 and other alleles
since the 1980s.
An efficient 2D6 metabolic pathway is required in order to metabolize more than
25% of all psyche drugs. Polymorphism of cytochrome P450 is significant in the
population. As much as 7-10% of Caucasians, for example, are poor metabolizers
or absent 2D6; 20% of Tanzanian Africans. A limited demographic chart can be
found at
http://www.pharmacologyweekly.com/table-cyp2d6-genetic-polymorphisms-pharmacogenetics
. A list of the drugs that need the 2D6 and other alleles can be found
http://vaccineliberationarmy.com/wp-content/uploads/2011/08/CYP-450-table-PDF.pdf
More frequently pharmaceutical manufacturers are being sued, settling cases and
paying out millions of dollars for Failure To Warn. For example, it was
successfully argued that the Eli Lilly Company failed to publicize research
showing some people are “poor metabolizers of Prozac” while a test can reveal if
a patient might be affected.
Cassidy
vs. Eli Lilly, 2002
Soon Hospitals and Psychiatrists will join the ranks of failed defendants, as
medical malpractice attorneys become educated in the subject of gene testing and
psychiatry, thereby opening up channels for multiple level litigations. Due to
the ever expanding field of pharmacogenetics, and the ever increasing inclusion
of information on Cytochrome P450 in manufacturers’ package inserts,
(specifically information on 2D6) there is no question that psychiatric
directors of hospitals, mental health clinics directors and psychiatrists in
general have working knowledge and have, indeed, had sufficient knowledge of
genetic polymorphism of Cytochrome P450 2D6 and other alleles for the past 10-15
years. Clearly disregarding this knowledge, psychiatrists have “failed to warn”
their patients putting them in harms way and the public at great risk.
Regards,
Eileen Dannemann
ncowmail@gmail.com